GLP-1 receptor agonists were associated with a higher risk for eye complications vs. other diabetes medications, two studies recently published in Annals of Internal Medicine show.Prior evidence on the ties between eye complications and GLP-1s has been mixed. A 2025 analysis indicated that semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) raise the risk for nonarteritic anterior ischemic optic…
Source: Healio News
